The North America Large Molecule Drug Substance CDMO Market should witness market growth of 8.0% CAGR during the forecast period (2022-2028).
In the drug development and pharmacology sectors, molecules are mainly classified as small and large. This difference between the sizes of the molecules also helps in understanding their behavior, transportation or mode of action, suitability, and adaptability for a different forms of drugs.
Presently, most medicines available in the market have been developed from small molecules, but large molecules are rapidly increasing in importance and usability. Drug development from large molecules is divided into drug substance development and drug product development.
The development of drug substance (DS) includes the development of working and master cell banks, scale-up, and manufacturing process development. Drug product (DP) development involves filling the substance into its container. The measurement and characterization guidelines for these processes are provided by the International Council for Harmonization (ICH).
The region collectively spends a lot in the R&D of biopharmaceuticals and, as a result, has become a significant producer of biologics. For example, Canada is among the top manufacturers of vaccines. In addition, some major national and international vaccine-producing firms exist nationwide. Similarly, the US government’s economy is significantly impacted by growing healthcare spending. This has also placed a burden on the populace to support this spending through ways like taxes or long-term borrowing.
The US market dominated the North America Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4, 180.9 million by 2028. The Canada market is poised to grow at a CAGR of 10.5% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 9.5% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
In the drug development and pharmacology sectors, molecules are mainly classified as small and large. This difference between the sizes of the molecules also helps in understanding their behavior, transportation or mode of action, suitability, and adaptability for a different forms of drugs.
Presently, most medicines available in the market have been developed from small molecules, but large molecules are rapidly increasing in importance and usability. Drug development from large molecules is divided into drug substance development and drug product development.
The development of drug substance (DS) includes the development of working and master cell banks, scale-up, and manufacturing process development. Drug product (DP) development involves filling the substance into its container. The measurement and characterization guidelines for these processes are provided by the International Council for Harmonization (ICH).
The region collectively spends a lot in the R&D of biopharmaceuticals and, as a result, has become a significant producer of biologics. For example, Canada is among the top manufacturers of vaccines. In addition, some major national and international vaccine-producing firms exist nationwide. Similarly, the US government’s economy is significantly impacted by growing healthcare spending. This has also placed a burden on the populace to support this spending through ways like taxes or long-term borrowing.
The US market dominated the North America Large Molecule Drug Substance CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $4, 180.9 million by 2028. The Canada market is poised to grow at a CAGR of 10.5% during (2022-2028). Additionally, The Mexico market should witness a CAGR of 9.5% during (2022-2028).
Based on Application, the market is segmented into Mammalian, Microbial and Others. Based on Service, the market is segmented into Contract Manufacturing and Contract Development. Based on Contract Manufacturing Type, the market is segmented into Commercial and Clinical. Based on Contract Development Type, the market is segmented into Cell Line Development and Process Development. Based on End-user, the market is segmented into Biotech Companies, CRO and Others. Based on countries, the market is segmented into U.S., Mexico, Canada, and Rest of North America.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Eurofins Scientific SE, WuXi Biologics (Cayman), Inc, Catalent, Inc., Boehringer Ingelheim International GmbH, FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation), Samsung Biologics Co., Ltd. (Samsung Group), Rentschler Biopharma SE, AGC Biologics, Inc. (AGC, Inc.), Recipharm AB (EQT AB), and Siegfried Holding AG.
Scope of the Study
By Application
- Mammalian
- Microbial
- Others
By Service
- Contract Manufacturing
- Commercial
- Clinical
- Contract Development
- Cell Line Development
- Process Development
By End-user
- Biotech Companies
- CRO
- Others
By Country
- US
- Canada
- Mexico
- Rest of North America
Key Market Players
List of Companies Profiled in the Report:
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Large Molecule Drug Substance CDMO Market, by Application
1.4.2 North America Large Molecule Drug Substance CDMO Market, by Service
1.4.3 North America Large Molecule Drug Substance CDMO Market, by End-user
1.4.4 North America Large Molecule Drug Substance CDMO Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Geographical Expansions
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Partnerships, Collaborations and Agreements: 2019, Apr- 2022, Oct) Leading Players
3.3.3 Key Strategic Move: (Acquisitions and Mergers : 2018, Oct - 2022, Aug) Leading Players
Chapter 4. North America Large Molecule Drug Substance CDMO Market by Application
4.1 North America Mammalian Market by Country
4.2 North America Microbial Market by Country
4.3 North America Other Application Market by Country
Chapter 5. North America Large Molecule Drug Substance CDMO Market by Service
5.1 North America Contract Manufacturing Market by Country
5.2 North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
5.2.1 North America Commercial Market by Country
5.2.2 North America Clinical Market by Country
5.3 North America Contract Development Market by Country
5.4 North America Large Molecule Drug Substance CDMO Market by Contract Development Type
5.4.1 North America Cell Line Development Market by Country
5.4.2 North America Process Development Market by Country
Chapter 6. North America Large Molecule Drug Substance CDMO Market by End-user
6.1 North America Biotech Companies Market by Country
6.2 North America CRO Market by Country
6.3 North America Others Market by Country
Chapter 7. North America Large Molecule Drug Substance CDMO Market by Country
7.1 US Large Molecule Drug Substance CDMO Market
7.1.1 US Large Molecule Drug Substance CDMO Market by Application
7.1.2 US Large Molecule Drug Substance CDMO Market by Service
7.1.2.1 US Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.1.2.2 US Large Molecule Drug Substance CDMO Market by Contract Development Type
7.1.3 US Large Molecule Drug Substance CDMO Market by End-user
7.2 Canada Large Molecule Drug Substance CDMO Market
7.2.1 Canada Large Molecule Drug Substance CDMO Market by Application
7.2.2 Canada Large Molecule Drug Substance CDMO Market by Service
7.2.2.1 Canada Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.2.2.2 Canada Large Molecule Drug Substance CDMO Market by Contract Development Type
7.2.3 Canada Large Molecule Drug Substance CDMO Market by End-user
7.3 Mexico Large Molecule Drug Substance CDMO Market
7.3.1 Mexico Large Molecule Drug Substance CDMO Market by Application
7.3.2 Mexico Large Molecule Drug Substance CDMO Market by Service
7.3.2.1 Mexico Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.3.2.2 Mexico Large Molecule Drug Substance CDMO Market by Contract Development Type
7.3.3 Mexico Large Molecule Drug Substance CDMO Market by End-user
7.4 Rest of North America Large Molecule Drug Substance CDMO Market
7.4.1 Rest of North America Large Molecule Drug Substance CDMO Market by Application
7.4.2 Rest of North America Large Molecule Drug Substance CDMO Market by Service
7.4.2.1 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Manufacturing Type
7.4.2.2 Rest of North America Large Molecule Drug Substance CDMO Market by Contract Development Type
7.4.3 Rest of North America Large Molecule Drug Substance CDMO Market by End-user
Chapter 8. Company Profiles
8.1 Teledyne FLIR LLC (Teledyne Technologies Incorporated)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Recent strategies and developments:
8.1.4.1 Partnerships, Collaborations and Agreements:
8.1.4.2 Product Launches and Product Expansions:
8.1.5 SWOT Analysis
8.2 Hikvision Digital Technology Co., Ltd., (China Electronics Technology Group Corporation)
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.2.4 Recent strategies and developments:
8.2.4.1 Partnerships, Collaborations, and Agreements:
8.2.4.2 Product Launches and Product Expansions:
8.3 Axis Communications AB (Canon, Inc.)
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expenses
8.3.5 Recent strategies and developments:
8.3.5.1 Partnerships, Collaborations, and Agreements:
8.3.5.2 Product Launches and Product Expansions:
8.4 Bosch Security Systems GmbH (Robert Bosch GmbH)
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Segmental and Regional Analysis
8.4.4 Research & Development Expense
8.4.5 Recent strategies and developments:
8.4.5.1 Product Launches and Product Expansions:
8.5 Avigilon Corporation (Motorola Solutions)
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional & Segmental Analysis
8.5.4 Research & Development Expenses
8.6 Hanwha Techwin Co., Ltd. (Hanwha Group)
8.6.1 Company Overview
8.6.2 Recent strategies and developments:
8.6.2.1 Partnerships, Collaborations, and Agreements:
8.6.2.2 Product Launches and Product Expansions:
8.7 Zhejiang Dahua Technology Co., Ltd.
8.7.1 Company Overview
8.7.2 Recent strategies and developments:
8.7.2.1 Product Launches and Product Expansions:
8.8 Zhejiang Uniview Technologies Co., Ltd. (Hangzhou Jiaozhi Technology Co., Ltd.)
8.8.1 Company Overview
8.8.2 Recent strategies and developments:
8.8.2.1 Partnerships, Collaborations, and Agreements:
Companies Mentioned
- Eurofins Scientific SE
- WuXi Biologics (Cayman), Inc
- Catalent, Inc.
- Boehringer Ingelheim International GmbH
- FUJIFILM Diosynth Biotechnologies Texas LLC (Fujifilm Corporation)
- Samsung Biologics Co., Ltd. (Samsung Group)
- Rentschler Biopharma SE
- AGC Biologics, Inc. (AGC, Inc.)
- Recipharm AB (EQT AB)
- Siegfried Holding AG
Methodology
LOADING...
